 Recombinant granulocyte-macrophage colony-stimulating factor autologous bone marrow transplantation lymphoid cancer BACKGROUND period neutropenia autologous bone marrow transplantation results substantial morbidity mortality results previous phase I-II clinical trials recombinant human granulocyte-macrophage colony-stimulating factor rhGM-CSF neutrophil recovery complications patients autologous bone marrow transplantation METHODS double-blind placebo-controlled trial institutions study design treatment schedules identical results analysis twenty-eight patients Sixty-five patients rhGM-CSF two-hour intravenous infusion days hours marrow infusion patients RESULTS No toxic effects patients rhGM-CSF recovery neutrophil count liter days patients placebo days infections days antibiotic administration days days initial hospitalization median days difference survival rate day CONCLUSIONS patients autologous bone marrow transplantation lymphoid neoplasia rhGM-CSF morbidity Further studies optimal dosage schedule administration